FDG PET imaging in hereditary thyroid cancer

Eur J Surg Oncol. 2003 Dec;29(10):922-8. doi: 10.1016/s0748-7983(03)00137-9.

Abstract

Aim: To report the role of different imaging methods in staging individuals with multiple endocrine neoplasia 2A (MEN2A) or familial medullary thyroid carcinoma (FMTC).

Material and methods: Fourteen newly diagnosed gene carriers underwent cervical ultrasound scanning (US), cervical and mediastinal CT, MRI and whole-body meta-[131I]iodobenzylguanidine (MIBG) scintigraphy and [18F]fluorodeoxyglucose (FDG) PET scanning.

Results: US identified seven true primary cancer. CT and MRI located only tumors > or =5 mm in diameter. MIBG scintigraphy and FDG PET could not identify MTC foci within the thyroid. Whole-body FDG PET identified two true-positive and one false-positive lymph node metastases. MIBG scintigraphy did not identify lymph node metastases. Total thyroidectomy was performed in 12 cases, and subtotal thyroidectomy in two subjects.

Conclusions: Whole-body FDG PET and cervical US help stage individuals carrying mutant genes verifying MEN2A or FMTC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Carcinoma, Medullary / diagnostic imaging*
  • Carcinoma, Medullary / genetics
  • Carcinoma, Medullary / surgery
  • Child
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Middle Aged
  • Multiple Endocrine Neoplasia Type 2a / diagnostic imaging*
  • Multiple Endocrine Neoplasia Type 2a / genetics
  • Multiple Endocrine Neoplasia Type 2a / surgery
  • Neoplasm Staging
  • Radiopharmaceuticals*
  • Thyroid Neoplasms / diagnostic imaging*
  • Thyroid Neoplasms / genetics
  • Thyroid Neoplasms / surgery
  • Tomography, Emission-Computed*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18